{"id":3633,"date":"2016-04-22T16:54:29","date_gmt":"2016-04-22T16:54:29","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=3633"},"modified":"2016-04-22T16:54:29","modified_gmt":"2016-04-22T16:54:29","slug":"therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\/","title":{"rendered":"Therapie der Hypertonie: Betablocker erh\u00f6hen bei \u00e4lteren Patienten das Risiko f\u00fcr orthostatische Hypotension"},"content":{"rendered":"<p>AMB 2016, 50, 28 Therapie der Hypertonie: Betablocker erh\u00f6hen bei \u00e4lteren Patienten das Risiko f\u00fcr orthostatische Hypotension Fazit: Es gibt \u00fcberzeugende Hinweise darauf, dass Betablocker bei \u00e4lteren Patienten mit arterieller Hypertonie vermehrt zu orthostatischer Hypotonie und St\u00fcrzen f\u00fchren. RAAS-Hemmer, Kalziumantagonisten und Diuretika scheinen diesbez\u00fcglich weniger problematisch zu sein. Betablocker sollten bei \u00e4lteren Menschen als Antihypertensivum [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2016, 50, 28 Therapie der Hypertonie: Betablocker erh\u00f6hen bei \u00e4lteren Patienten das Risiko f\u00fcr orthostatische Hypotension Fazit: Es gibt \u00fcberzeugende Hinweise darauf, dass Betablocker bei \u00e4lteren Patienten mit arterieller Hypertonie vermehrt zu orthostatischer Hypotonie und St\u00fcrzen f\u00fchren. RAAS-Hemmer, Kalziumantagonisten und Diuretika scheinen diesbez\u00fcglich weniger problematisch zu sein. Betablocker sollten bei \u00e4lteren Menschen als Antihypertensivum [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[1558,98,2363,81,80,82,936,2359,2352,1598,2360,99,2361,831,2358,193,2353,1600,988,1602,420,107,2356,550,2357,2335,2354,2362,2355,554],"class_list":["post-3633","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-antihypertensiva","tag-arzneimittel","tag-b-proof-studie","tag-beta-blocker","tag-betablocker","tag-betarezeptoren-blocker","tag-diuretika","tag-glyceroltrinitrat","tag-hypotension","tag-levodopa","tag-mao-hemmer","tag-medikamente","tag-monoaminooxidase-hemmer","tag-morphin","tag-nitroglycerin","tag-olanzapin","tag-orthostatische-hypotension","tag-pramipexol","tag-risperidon","tag-ropinirol","tag-selektive-serotonin-wiederaufnahme-hemmer","tag-serotonin-wiederaufnahme-hemmer","tag-sildenafil","tag-stuerze","tag-tadalafil","tag-temazepam","tag-terazosin","tag-tilda-studie","tag-tizanidin","tag-trizyklische-antidepressiva"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Therapie der Hypertonie: Betablocker erh\u00f6hen bei \u00e4lteren Patienten das Risiko f\u00fcr orthostatische Hypotension<\/title>\n<meta name=\"description\" content=\"Therapie der Hypertonie: Betablocker erh\u00f6hen bei \u00e4lteren Patienten das Risiko f\u00fcr orthostatische Hypotension -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Therapie der Hypertonie: Betablocker erh\u00f6hen bei \u00e4lteren Patienten das Risiko f\u00fcr orthostatische Hypotension\" \/>\n<meta property=\"og:description\" content=\"Therapie der Hypertonie: Betablocker erh\u00f6hen bei \u00e4lteren Patienten das Risiko f\u00fcr orthostatische Hypotension -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2016-04-22T16:54:29+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg\" \/>\n<meta name=\"author\" content=\"Hiwot\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Hiwot\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\\\/\"},\"author\":{\"name\":\"Hiwot\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\"},\"headline\":\"Therapie der Hypertonie: Betablocker erh\u00f6hen bei \u00e4lteren Patienten das Risiko f\u00fcr orthostatische Hypotension\",\"datePublished\":\"2016-04-22T16:54:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\\\/\"},\"wordCount\":324,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"keywords\":[\"Antihypertensiva\",\"Arzneimittel\",\"B-PROOF-Studie\",\"Beta-Blocker\",\"Betablocker\",\"Betarezeptoren-Blocker\",\"Diuretika\",\"Glyceroltrinitrat\",\"Hypotension\",\"Levodopa\",\"MAO-Hemmer\",\"Medikamente\",\"Monoaminooxidase-Hemmer\",\"Morphin\",\"Nitroglycerin\",\"Olanzapin\",\"Orthostatische Hypotension\",\"Pramipexol\",\"Risperidon\",\"Ropinirol\",\"Selektive Serotonin-Wiederaufnahme-Hemmer\",\"Serotonin-Wiederaufnahme-Hemmer\",\"Sildenafil\",\"St\u00fcrze\",\"Tadalafil\",\"Temazepam\",\"Terazosin\",\"TILDA-Studie\",\"Tizanidin\",\"Trizyklische Antidepressiva\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\\\/\",\"name\":\"Therapie der Hypertonie: Betablocker erh\u00f6hen bei \u00e4lteren Patienten das Risiko f\u00fcr orthostatische Hypotension\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"datePublished\":\"2016-04-22T16:54:29+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\"},\"description\":\"Therapie der Hypertonie: Betablocker erh\u00f6hen bei \u00e4lteren Patienten das Risiko f\u00fcr orthostatische Hypotension -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Therapie der Hypertonie: Betablocker erh\u00f6hen bei \u00e4lteren Patienten das Risiko f\u00fcr orthostatische Hypotension\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\",\"name\":\"Hiwot\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"caption\":\"Hiwot\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Therapie der Hypertonie: Betablocker erh\u00f6hen bei \u00e4lteren Patienten das Risiko f\u00fcr orthostatische Hypotension","description":"Therapie der Hypertonie: Betablocker erh\u00f6hen bei \u00e4lteren Patienten das Risiko f\u00fcr orthostatische Hypotension -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\/","og_locale":"de_DE","og_type":"article","og_title":"Therapie der Hypertonie: Betablocker erh\u00f6hen bei \u00e4lteren Patienten das Risiko f\u00fcr orthostatische Hypotension","og_description":"Therapie der Hypertonie: Betablocker erh\u00f6hen bei \u00e4lteren Patienten das Risiko f\u00fcr orthostatische Hypotension -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2016-04-22T16:54:29+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","type":"","width":"","height":""}],"author":"Hiwot","twitter_misc":{"Verfasst von":"Hiwot","Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\/"},"author":{"name":"Hiwot","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c"},"headline":"Therapie der Hypertonie: Betablocker erh\u00f6hen bei \u00e4lteren Patienten das Risiko f\u00fcr orthostatische Hypotension","datePublished":"2016-04-22T16:54:29+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\/"},"wordCount":324,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","keywords":["Antihypertensiva","Arzneimittel","B-PROOF-Studie","Beta-Blocker","Betablocker","Betarezeptoren-Blocker","Diuretika","Glyceroltrinitrat","Hypotension","Levodopa","MAO-Hemmer","Medikamente","Monoaminooxidase-Hemmer","Morphin","Nitroglycerin","Olanzapin","Orthostatische Hypotension","Pramipexol","Risperidon","Ropinirol","Selektive Serotonin-Wiederaufnahme-Hemmer","Serotonin-Wiederaufnahme-Hemmer","Sildenafil","St\u00fcrze","Tadalafil","Temazepam","Terazosin","TILDA-Studie","Tizanidin","Trizyklische Antidepressiva"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\/","name":"Therapie der Hypertonie: Betablocker erh\u00f6hen bei \u00e4lteren Patienten das Risiko f\u00fcr orthostatische Hypotension","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","datePublished":"2016-04-22T16:54:29+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c"},"description":"Therapie der Hypertonie: Betablocker erh\u00f6hen bei \u00e4lteren Patienten das Risiko f\u00fcr orthostatische Hypotension -- UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/therapie-der-hypertonie-betablocker-erhoehen-bei-aelteren-patienten-das-risiko-fuer-orthostatische-hypotension\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Therapie der Hypertonie: Betablocker erh\u00f6hen bei \u00e4lteren Patienten das Risiko f\u00fcr orthostatische Hypotension"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c","name":"Hiwot","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","caption":"Hiwot"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3633","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=3633"}],"version-history":[{"count":1,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3633\/revisions"}],"predecessor-version":[{"id":3634,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3633\/revisions\/3634"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=3633"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=3633"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=3633"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}